• Praluent® is a fully human monoclonal antibody1 that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) from binding to LDL-Rs, increasing the number of LDL-Rs available to remove LDL-C from the circulation.1,2

    Without PCSK9 inhibition, PCSK9 decreases the number of available LDL-Rs on liver cells, resulting in higher LDL-C levels in the bloodstream.1

    PCSK9 inhibition with Praluent® increases the number of available LDL-Rs, resulting in lower LDL-C levels in the bloodstream.1

    Effects with of PCSK9 inhibition with Praluent®

    Figure © Sanofi.


    Watch the video below to learn more about the mechanism of action for Praluent®


    Learn more


    Learn more

    LDL-C=low-density lipoprotein cholesterol; LDL-R=low-density lipoprotein receptor; PCSK9i=proprotein convertase subtilisin/kexin type 9 inhibitor.

    1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed April 2022.
    2. Poirier S and Mayer G. Drug Des Devel Ther 2013;7:1135–1148.